Parikh, R. A., Herzberg, B., Stein, M. N., Kato, S., Barve, M. A., Spigel, D. R., Garmezy, B., Philipovskiy, A., Iyer, G., Cooper, A. J., Korpal, M., Cabanski, M., Ortiz, C. P., Tiedt, R., Cleary, L. D., Schmalbach, T., Warmuth, M., Janku, F., Spira, A. I. (2026). A phase 1/2 study of MRT-2359, a highly selective oral GSPT1 molecular glue degrader (MGD), in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) harboring AR ligand binding domain (LBD) mutations.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.161